Drugmaker AstraZeneca Pharma India Ltd. on Thursday said it will launch its Acalabrutinib 100 milligram capsules, used for treatment of various types of blood cancers, under the brand name 'Calquence' in the country on Oct. 21.
ADVERTISEMENT
The capsules are indicated for treatment of patients with mantle cell lymphoma who have received at least one prior therapy and for treatment of patients with chronic lymphocytic leukaemia and small lymphocytic lymphoma, AstraZeneca Pharma India said in a filing to the stock exchanges.
ADVERTISEMENT
Shares of AstraZeneca Pharma India Ltd. on Thursday closed 0.61% lower at Rs 4,266.65 apiece on the BSE.